DA Davidson analyst Rudy Kessinger downgrades Okta (NASDAQ:OKTA) from Buy to Neutral.
Gamida Cell Provides Regulatory Update On Omidubicel, Says Received Extension Of Omidubicel PDUFA Date From Jan. 30, 2023 To May 1, 2023 As FDA Issued Information Request
Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent
